CD58 and myeloid sarcoma: The data thus confirm the result of the HapMap cohort analysis, with individuals homozygous for the allele conferring risk of MS having a moderately lower level of CD58 gene transcripts than individuals homozygous for the alternative allele and heterozygous carriers showing an intermediate level of expression.